Novavax (NVAX) : Tuesdays money flow indicated an uptick to downtick ratio was at 1.41. The total value of inflow transactions on upticks was $2.41 million, whereas, the total value of outflow trades on downticks was $1.7 million. The total money flow was $0.7 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $0.38 million. The total value of the trades done on upticks was $0.46 million. Downticks saw transactions worth $0.08 million. The total uptick to downtick ratio stood at 5.95, mildly in favor of the bulls. Novavax (NVAX) was trading with a 0% change over previous days close. It fell $0 during the day and reached $7.77. The stock was 1.97% compared to the previous weeks close.
The company Insiders own 3.5% of Novavax shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -17.65% . Institutional Investors own 82.01% of Novavax shares. During last six month period, the net percent change held by insiders has seen a change of -16.33%. In an insider trading activity, The Securities and Exchange Commission has divulged that Evans Gary C, director of Novavax Inc, had unloaded 18,998 shares at an average price of $6.5 in a transaction dated on June 6, 2016. The total value of the transaction was worth $123,487.
Shares of Novavax, Inc. rose by 6.92% in the last five trading days and 19.11% for the last 4 weeks. Novavax, Inc. is up 41.32% in the last 3-month period. Year-to-Date the stock performance stands at -7.87%.
Novavax (NASDAQ:NVAX): On Tuesdays trading session , Opening price of the stock was $7.89 with an intraday high of $7.9. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $7.7. However, the stock managed to close at $7.73, a loss of 0.51% for the day. On the previous day, the stock had closed at $7.77. The total traded volume of the day was 4,113,220 shares.
Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).